Back to Search
Start Over
Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani.
- Source :
-
Vaccine [Vaccine] 2001 Apr 30; Vol. 19 (23-24), pp. 3104-15. - Publication Year :
- 2001
-
Abstract
- Leishmania donovani GP36 glycoprotein is the main antigen of the FML Fucose Mannose Ligand (FML) complex specifically recognized by sera of kala-azar human patients. The GP36 was isolated by chemical elution + sonication and used for Balb/c mouse vaccination in combination with saponin, by the s.c. route, inducing a strong and specific protective effect against experimental visceral leishmaniasis shown by the increase of: specific IgG antibodies (82.6%), mainly IgG2a, the delayed type of hypersensitivity to promastigote lysate (37.8%, P < 0.001), the in vitro cellular proliferative response to GP36 of ganglia lymphocytes (53.5%, P < 0.005) and the decrease of liver parasite burden (68.1%, P < 0.025). Saponin treated controls reacted significantly differently from GP36 vaccinated animals at all the assayed variables (P < 0.05). GP36 induced significant protection against murine visceral leishmaniasis at concentrations commonly used for vaccination with recombinant antigens.
- Subjects :
- Animals
Antibodies, Protozoan biosynthesis
Antigens, Protozoan isolation & purification
Female
Immunity, Cellular
Mice
Mice, Inbred BALB C
Protozoan Proteins administration & dosage
Protozoan Proteins immunology
Protozoan Proteins isolation & purification
Antigens, Protozoan administration & dosage
Leishmania donovani immunology
Leishmaniasis, Visceral immunology
Leishmaniasis, Visceral prevention & control
Protozoan Vaccines administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 0264-410X
- Volume :
- 19
- Issue :
- 23-24
- Database :
- MEDLINE
- Journal :
- Vaccine
- Publication Type :
- Academic Journal
- Accession number :
- 11312005
- Full Text :
- https://doi.org/10.1016/s0264-410x(01)00031-7